DDIT3 and diffuse large B-cell lymphoma: A Phase III clinical trial (LNH98-5) by the GELA (Groupe d’Etude des Lymphomes de l’Adulte), comparing 8 cycles of R-CHOP to 8 cycles of CHOP in 399 DLBCL patients age 60- 80 showed that R-CHOP increased the complete response (CR) rate from 60% to 76%, the event-free survival (EFS) from 49% to 68%, and the overall survival (OS) from 68% to 83%, compared to CHOP (4).